Šalis: Airija
kalba: anglų
Šaltinis: HPRA (Health Products Regulatory Authority)
ONDANSETRON
Arrow Generics Limited
4 Milligram
Film Coated Tablet
2010-03-19
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ondatab 4 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg Ondansetron hydrochloride dihydrate, equivalent to 4 mg Ondansetron Excipients: Each tablet contains 46 mg lactose monohydrate For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet White coloured, circular, biconvex film-coated tablets debossed with ‘4’ on one side and plain on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Adults: Management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Prevention and treatment of post-operative nausea and vomiting (PONV). Paediatric Population: Management of chemotherapy -induced nausea and vomiting in children aged 6 months. Prevention and treatment of post-operative nausea and vomiting in children aged 1 month. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral use. Chemotherapy and radiotherapy induced nausea and vomiting Adults: The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The route of administration and dose of ondansetron should be flexible in the range of 8- 32 mg a day and selected as shown below. Emetogenic Chemotherapy and Radiotherapy: Ondansetron can be given either by rectal, oral (tablets or syrup), intravenous or intramuscular administration. For most patients receiving emetogenic chemotherapy or radiotherapy, Ondansetron 8 mg should be administered as a slow intravenous or intramuscular injection immediately before treatment, followed by 8 mg orally twelve hourly. For oral administration: 8mg 1-2 hours before treatment, followed by 8mg 12 hours later. To protect against delayed or prolonged emesis after Perskaitykite visą dokumentą